Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
Search
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical
Marie Penzold
Marie Penzold talks about her career as a HR business partner in the Innovation unit here at Boehringer Ingelheim.
She finds purpose in the saddle and pursues a passion for horses – at home and work
She finds purpose in the saddle and pursues a passion for horses – at home and work
Retinal Diseases
Retinal Diseases
Contact Us
Contact Us
Pioneers who inspire: Women in livestock
Pioneers who inspire: Women in livestock
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Focus on Alliance Management
Focus on Alliance Management
Boehringer Ingelheim Cares Product Donations Program
Boehringer Ingelheim Cares Product Donations Program
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
BI Cares Financial Contributions Program
BI Cares Financial Contributions Program
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
The View from Both Sides of the Table
The View from Both Sides of the Table
Cleaning up the coast for a greener future
Employees from our Fremont site connect with nature and clean up the environment.
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
Boehringer Ingelheim - Life Forward
Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal
J-Code Issued for SPEVIGO
Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger
Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.
FDA approves the first treatment option for generalized pustular psoriasis flares in adults
FDA approves the first treatment option for generalized pustular psoriasis flares in adults